Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
4.17% $1.750
America/New_York / 26 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 42.97 mill |
EPS: | -2.44 |
P/E: | -0.720 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 24.55 mill |
Avg Daily Volume: | 0.348 mill |
RATING 2024-04-26 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.720 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.12x |
Company: PE -0.720 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.618 - 1.882 ( +/- 7.54%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-23 | Ball Bryan | Sell | 0 | Common Stock |
2024-04-23 | Ball Bryan | Sell | 147 500 | Stock option (right to buy) |
2024-04-23 | Ball Bryan | Sell | 50 000 | Stock option (right to buy) |
2024-04-23 | Ball Bryan | Sell | 40 000 | Stock option (right to buy) |
2024-04-23 | Ball Bryan | Sell | 20 000 | Restricted Stock Units |
INSIDER POWER |
---|
48.05 |
Last 93 transactions |
Buy: 5 312 775 | Sell: 1 005 050 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.750 (4.17% ) |
Volume | 0.147 mill |
Avg. Vol. | 0.348 mill |
% of Avg. Vol | 42.23 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.